{
    "claims": [
        {
            "claim_id": "C01",
            "claim": "Intratumoral mRNA vaccination enhances the diversity of antigens presented on tumor cells.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3%",
                    "line_ref": "L28"
                },
                {
                    "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6%",
                    "line_ref": "L29"
                }
            ],
            "caveat": "The effect is demonstrated in mouse models and the breadth of applicability to human tumors is not fully established."
        },
        {
            "claim_id": "C02",
            "claim": "mRNA vaccination in tumors induces a type I interferon response, a key step in immune activation.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0",
                    "line_ref": "L31"
                },
                {
                    "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
                    "line_ref": "L42"
                }
            ],
            "caveat": "The magnitude of the interferon response may vary between different tumor types and microenvironments."
        },
        {
            "claim_id": "C03",
            "claim": "The combination of intratumoral mRNA vaccination and anti-PD-L1 therapy improves tumor control in preclinical models.",
            "strength": "strong",
            "evidence": [
                {
                    "quote": "Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x",
                    "line_ref": "L33"
                },
                {
                    "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
                    "line_ref": "L46"
                }
            ],
            "caveat": "These are preclinical results in mice, and may not directly translate to human clinical outcomes."
        },
        {
            "claim_id": "C04",
            "claim": "Prior mRNA vaccination is associated with improved survival in metastatic patients treated with ICIs.",
            "strength": "tentative",
            "evidence": [
                {
                    "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A",
                    "line_ref": "L30"
                },
                {
                    "quote": "The human analysis is retrospective and non-randomized; residual confounding is likely.",
                    "line_ref": "L49"
                }
            ],
            "caveat": "This is a retrospective, non-randomized analysis, so the association may be due to confounding variables rather than a causal effect of the vaccine."
        }
    ]
}